Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyBrigitta G. Baumert, Roger Stupp, Gail Ryan et al.|The Lancet Oncology|2016Cited by 504
Influence of Nucleoshuttling of the ATM Protein in the Healthy Tissues Response to Radiation Therapy: Toward a Molecular Classification of Human RadiosensitivityAdeline Granzotto, S. Racadot, Mohamed Amine Benadjaoud et al.|International Journal of Radiation Oncology*Biology*Physics|2015Cited by 122
BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort studyDario De Alcubierre, Emmanuel Jouanneau, Grigorios Gkasdaris et al.|European Journal of Endocrinology|2024Cited by 23
Medical debulking with BRAF/MEK inhibitors in aggressive <i>BRAF</i>-mutant craniopharyngiomaAnna Luisa Di Stefano, S. Gaillard, David Guyon et al.|Neuro-Oncology Advances|2020Cited by 23
Outcome of giant pituitary tumors requiring surgeryS. Gaillard, Bertrand Baussart, Sosthène Adéniran et al.|Frontiers in Endocrinology|2022Cited by 18